H. Lieu

发表

Regadenoson Pharmacokinetics and Tolerability in Subjects With Impaired Renal Function

B. Blackburn, T. Gordi, H. Lieu, 2007, Journal of clinical pharmacology.

A Population Pharmacokinetic/Pharmacodynamic Analysis of Regadenoson, an Adenosine A2A-Receptor Agonist, in Healthy Male Volunteers

L. Belardinelli, A. Wolff, T. Gordi, 2006, Clinical pharmacokinetics.

Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans

R. Kerensky, J. Shryock, L. Belardinelli, 2007, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial

P. Barnes, B. Leaker, T. Hansel, 2008, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial.

P. Nguyen, P. Kaufmann, T. Schepis, 2008, Journal of the American College of Cardiology.

Designer Natriuretic Peptides

J. Burnett, H. Lieu, Candace Y. W. Lee, 2009, Journal of Investigative Medicine.

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.

J. Trotter, J. Frias, C. Guy, 2020, Gastroenterology.

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.

P. Thuluvath, M. Kipnes, M. Abdelmalek, 2022, The lancet. Gastroenterology & hepatology.

Myocardial perfusion imaging.

G. Thomas, H. Lieu, 1977 .

Pharmacodynamics Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD‐NP, in a First‐in‐Human Clinical Trial in Healthy Subjects

S. Swan, J. Burnett, Horng H. Chen, 2009, Journal of clinical pharmacology.

Veillonella as a bile acid-sensitive bacteria and a microbiome-based biomarker for aldafermin (NGM282) in patients with non-alcoholic steatohepatitis

A. Sanyal, R. Loomba, Duy M. Dinh, 2020, Journal of Hepatology.

Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases

A. Sanyal, G. Hirschfield, U. Beuers, 2021, JHEP reports : innovation in hepatology.

Abstract 11106: The Compass Trial (NCT01117506): A Prospective Multi-Center, Double-Blind Study Assessing a Whole Blood Gene Expression Test for the Detection Of Obstructive Coronary Artery Disease in Symptomatic Patients Referred for Myocardial Perfusion Imaging

A. Lansky, G. Thomas, J. Mcpherson, 2011 .

Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial

Robert C. Hendel, John J. Mahmarian, Manuel D. Cerqueira, 2007, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future

D. Sim, P. Andre, H. Lieu, 2008, Biomarker insights.

Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States

Zhenxiang Zhao, M. Effron, J. Bae, 2014, Current medical research and opinion.

Genetic control of autoimmune myocarditis mediated by myosin-specific antibodies

B. Diamond, S. Factor, B. Kotzin, 1999, Immunogenetics.

Eliminating Atherogenesis in Mice by Switching Off Hepatic Lipoprotein Secretion

S. Young, E. Fisher, R. Walzem, 2003, Circulation.

The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH

A. Sanyal, R. Loomba, S. Harrison, 2020, Hepatology.

Whole Blood Gene Expression Testing for Coronary Artery Disease in Nondiabetic Patients: Major Adverse Cardiovascular Events and Interventions in the PREDICT Trial

W. Kraus, E. Topol, S. Ellis, 2012, Journal of Cardiovascular Translational Research.

Trial to Evaluate the Management of Paroxysmal Supraventricular Tachycardia During an Electrophysiology Study With Tecadenoson

J. Camm, E. Prystowsky, K. Ellenbogen, 2005, Circulation.

A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging The COMPASS Study

P. Douglas, A. Lansky, G. Thomas, 2013, Circulation. Cardiovascular genetics.

The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging

Randall C. Thompson, G. Thomas, M. Miyamoto, 2009, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel.

Zhenxiang Zhao, M. Effron, J. Bae, 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion

Steven, P. Douglas, A. Lansky, 2013 .

“Real‐World” Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States

Won Chan Lee, M. Effron, G. Vetrovec, 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

On the Physiological Importance of Endoproteolysis of CAAX Proteins

J. Otto, P. Casey, M. Bergo, 2004, Journal of Biological Chemistry.

A PERIPHERAL BLOOD GENE EXPRESSION SCORE FOR CORONARY ARTERY DISEASE IN NON-DIABETIC PATIENTS IDENTIFIES PATIENTS AT LOW RISK FOR MAJOR CARDIOVASCULAR EVENTS AND INTERVENTIONAL PROCEDURES IN THE NEXT 12 MONTHS

W. Kraus, E. Topol, S. Ellis, 2012 .

Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in non-alcoholic steatohepatitis and primary sclerosing cholangitis patients

M. Karsdal, J. Trotter, G. Hirschfield, 2020, Journal of Hepatology.

INITIAL INTRAVENOUS EXPERIENCE WITH PRT060128 (PRT128), AN ORALLY-AVAILABLE, DIRECT-ACTING, AND REVERSIBLE P2Y12 INHIBITOR

P. Conley, D. Phillips, P. Leese, 2007 .

Initial Observations of Intravenous CD-NP, Chimeric Natriuretic Peptide, on Renal Functions in Chronic Heart Failure Patients

B. Massie, S. Goldsmith, J. Burnett, 2009 .

A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging The COMPASS Study

P. Douglas, A. Lansky, G. Thomas, 2013, Circulation. Cardiovascular genetics.

INITIAL EXPERIENCE WITH SUBCUTANEOUS INFUSION OF CENDERITIDE IN PATIENTS WITH CHRONIC HEART FAILURE

S. Goldsmith, J. Burnett, M. Koren, 2012 .